|
1
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al European Organisation for Research and Treatment of Cancer
Brain Tumor and Radiotherapy Groups; National Cancer Institute of
Canada Clinical Trials Group: Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Alifieris C and Trafalis DT: Glioblastoma
multiforme: Pathogenesis and treatment. Pharmacol Ther. 152:63–82.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mair B, Kubicek S and Nijman SM:
Exploiting epigenetic vulnerabilities for cancer therapeutics.
Trends Pharmacol Sci. 35:136–145. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huang M, Shen A, Ding J and Geng M:
Molecularly targeted cancer therapy: Some lessons from the past
decade. Trends Pharmacol Sci. 35:41–50. 2014. View Article : Google Scholar
|
|
5
|
Bouteldja N, Andersen LT, Møller N and
Gormsen LC: Using positron emission tomography to study human
ketone body metabolism: A review. Metabolism. 63:1375–1384. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Reardon DA and Wen PY: Glioma in 2014:
Unravelling tumour heterogeneity-implications for therapy. Nat Rev
Clin Oncol. 12:69–70. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nicolaidis S: Biomarkers of glioblastoma
multiforme. Metabolism. 64(Suppl 1): S22–S27. 2015. View Article : Google Scholar
|
|
8
|
Chiarini F, Evangelisti C, McCubrey JA and
Martelli AM: Current treatment strategies for inhibiting mTOR in
cancer. Trends Pharmacol Sci. 36:124–135. 2015. View Article : Google Scholar
|
|
9
|
Ji H, Wang J, Nika H, Hawke D, Keezer S,
Ge Q, Fang B, Fang X, Fang D, Litchfield DW, et al: EGF-induced ERK
activation promotes CK2-mediated disassociation of alpha-catenin
from beta-catenin and transactivation of beta-catenin. Mol Cell.
36:547–559. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Miao H, Li DQ, Mukherjee A, Guo H, Petty
A, Cutter J, Basilion JP, Sedor J, Wu J, Danielpour D, et al: EphA2
mediates ligand-dependent inhibition and ligand-independent
promotion of cell migration and invasion via a reciprocal
regulatory loop with Akt. Cancer Cell. 16:9–20. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim E, Kim M, Woo DH, Shin Y, Shin J,
Chang N, Oh YT, Kim H, Rheey J, Nakano I, et al: Phosphorylation of
EZH2 activates STAT3 signaling via STAT3 methylation and promotes
tumorigenicity of glioblastoma stem-like cells. Cancer Cell.
23:839–852. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Herskovits AZ and Guarente L: Sirtuin
deacetylases in neurode-generative diseases of aging. Cell Res.
23:746–758. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Haigis MC and Guarente LP: Mammalian
sirtuins - emerging roles in physiology, aging, and calorie
restriction. Genes Dev. 20:2913–2921. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hubbard BP and Sinclair DA: Small molecule
SIRT1 activators for the treatment of aging and age-related
diseases. Trends Pharmacol Sci. 35:146–154. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Polak-Jonkisz D, Rehan L, Laszki-Szcząchor
K and Sobieszczańska M: Novel targets for pharmacological
intervention in age-related diseases. Trends Pharmacol Sci.
35:622–623. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Imai S and Guarente L: NAD+ and
sirtuins in aging and disease. Trends Cell Biol. 24:464–471. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Peng G and Liu Y: Hypoxia-inducible
factors in cancer stem cells and inflammation. Trends Pharmacol
Sci. 36:374–383. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Davis FM, Stewart TA, Thompson EW and
Monteith GR: Targeting EMT in cancer: Opportunities for
pharmacological intervention. Trends Pharmacol Sci. 35:479–488.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang SJ and Lim Y: Resveratrol ameliorates
hepatic metaflammation and inhibits NLRP3 inflammasome activation.
Metabolism. 63:693–701. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shimada T, Furuta H, Doi A, Ariyasu H,
Kawashima H, Wakasaki H, Nishi M, Sasaki H and Akamizu T: Des-acyl
ghrelin protects microvascular endothelial cells from oxidative
stress-induced apoptosis through sirtuin 1 signaling pathway.
Metabolism. 63:469–474. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen J, Zhang B, Wong N, Lo AW, To KF,
Chan AW, Ng MH, Ho CY, Cheng SH, Lai PB, et al: Sirtuin 1 is
upregulated in a subset of hepatocellular carcinomas where it is
essential for telomere maintenance and tumor cell growth. Cancer
Res. 71:4138–4149. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang P, Xu TY, Guan YF, Tian WW, Viollet
B, Rui YC, Zhai QW, Su DF and Miao CY: Nicotinamide
phosphoribosyltransferase protects against ischemic stroke through
SIRT1-dependent adenosine monophosphate-activated kinase pathway.
Ann Neurol. 69:360–374. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Prozorovski T, Schulze-Topphoff U, Glumm
R, Baumgart J, Schröter F, Ninnemann O, Siegert E, Bendix I,
Brüstle O, Nitsch R, et al: Sirt1 contributes critically to the
redox-dependent fate of neural progenitors. Nat Cell Biol.
10:385–394. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao Y, Guan YF, Zhou XM, Li GQ, Li ZY,
Zhou CC, Wang P and Miao CY: Regenerative neurogenesis after
ischemic stroke promoted by nicotinamide
phosphoribosyltransferase-nicotinamide adenine dinucleotide
cascade. Stroke. 46:1966–1974. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Michishita E, McCord RA, Berber E, Kioi M,
Padilla-Nash H, Damian M, Cheung P, Kusumoto R, Kawahara TL,
Barrett JC, et al: SIRT6 is a histone H3 lysine 9 deacetylase that
modulates telomeric chromatin. Nature. 452:492–496. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jiang H, Khan S, Wang Y, Charron G, He B,
Sebastian C, Du J, Kim R, Ge E, Mostoslavsky R, et al: SIRT6
regulates TNF-α secretion through hydrolysis of long-chain fatty
acyl lysine. Nature. 496:110–113. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee J, Hong SW, Park SE, Rhee EJ, Park CY,
Oh KW, Park SW and Lee WY: Exendin-4 regulates lipid metabolism and
fibroblast growth factor 21 in hepatic steatosis. Metabolism.
63:1041–1048. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mostoslavsky R, Chua KF, Lombard DB, Pang
WW, Fischer MR, Gellon L, Liu P, Mostoslavsky G, Franco S, Murphy
MM, et al: Genomic instability and aging-like phenotype in the
absence of mammalian SIRT6. Cell. 124:315–329. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sebastián C, Zwaans BM, Silberman DM,
Gymrek M, Goren A, Zhong L, Ram O, Truelove J, Guimaraes AR, Toiber
D, et al: The histone deacetylase SIRT6 is a tumor suppressor that
controls cancer metabolism. Cell. 151:1185–1199. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Marquardt JU, Fischer K, Baus K, Kashyap
A, Ma S, Krupp M, Linke M, Teufel A, Zechner U, Strand D, et al:
Sirtuin-6-dependent genetic and epigenetic alterations are
associated with poor clinical outcome in hepatocellular carcinoma
patients. Hepatology. 58:1054–1064. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Khongkow M, Olmos Y, Gong C, Gomes AR,
Monteiro LJ, Yagüe E, Cavaco TB, Khongkow P, Man EP, Laohasinnarong
S, et al: SIRT6 modulates paclitaxel and epirubicin resistance and
survival in breast cancer. Carcinogenesis. 34:1476–1486. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Feng XX, Luo J, Liu M, Yan W, Zhou ZZ, Xia
YJ, Tu W, Li PY, Feng ZH and Tian DA: Sirtuin 6 promotes
transforming growth
factor-β1/H2O2/HOCl-mediated enhancement of
hepato-cellular carcinoma cell tumorigenicity by suppressing
cellular senescence. Cancer Sci. 106:559–566. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang P, Xu TY, Guan YF, Su DF, Fan GR and
Miao CY: Perivascular adipose tissue-derived visfatin is a vascular
smooth muscle cell growth factor: Role of nicotinamide
mononucleotide. Cardiovasc Res. 81:370–380. 2009. View Article : Google Scholar
|
|
34
|
Magzoub M and Miranker AD:
Concentration-dependent transitions govern the subcellular
localization of islet amyloid polypeptide. FASEB J. 26:1228–1238.
2012. View Article : Google Scholar :
|
|
35
|
Wang P, Guan YF, Du H, Zhai QW, Su DF and
Miao CY: Induction of autophagy contributes to the neuroprotection
of nicotinamide phosphoribosyltransferase in cerebral ischemia.
Autophagy. 8:77–87. 2012. View Article : Google Scholar
|
|
36
|
Tönjes M, Barbus S, Park YJ, Wang W,
Schlotter M, Lindroth AM, Pleier SV, Bai AH, Karra D, Piro RM, et
al: BCAT1 promotes cell proliferation through amino acid catabolism
in gliomas carrying wild-type IDH1. Nat Med. 19:901–908. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Song J, Ke SF, Zhou CC, Zhang SL, Guan YF,
Xu TY, Sheng CQ, Wang P and Miao CY: Nicotinamide
phosphoribosyltransferase is required for the calorie
restriction-mediated improvements in oxidative stress,
mitochondrial biogenesis, and metabolic adaptation. J Gerontol A
Biol Sci Med Sci. 69:44–57. 2014. View Article : Google Scholar
|
|
38
|
Wang P, Du H, Zhou CC, Song J, Liu X, Cao
X, Mehta JL, Shi Y, Su DF and Miao CY: Intracellular
NAMPT-NAD+-SIRT1 cascade improves post-ischaemic
vascular repair by modulating Notch signalling in endothelial
progenitors. Cardiovasc Res. 104:477–488. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang P, Xu TY, Wei K, Guan YF, Wang X, Xu
H, Su DF, Pei G and Miao CY: ARRB1/β-arrestin-1 mediates
neuroprotection through coordination of BECN1-dependent autophagy
in cerebral ischemia. Autophagy. 10:1535–1548. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rousseau A, Mokhtari K and Duyckaerts C:
The 2007 WHO classification of tumors of the central nervous system
- what has changed? Curr Opin Neurol. 21:720–727. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gorrini C, Harris IS and Mak TW:
Modulation of oxidative stress as an anticancer strategy. Nat Rev
Drug Discov. 12:931–947. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lo HW, Cao X, Zhu H and Ali-Osman F:
Constitutively activated STAT3 frequently coexpresses with
epidermal growth factor receptor in high-grade gliomas and
targeting STAT3 sensitizes them to Iressa and alkylators. Clin
Cancer Res. 14:6042–6054. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liszt G, Ford E, Kurtev M and Guarente L:
Mouse Sir2 homolog SIRT6 is a nuclear ADP-ribosyltransferase. J
Biol Chem. 280:21313–21320. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lee OH, Kim J, Kim JM, Lee H, Kim EH, Bae
SK, Choi Y, Nam HS and Heo JH: Decreased expression of sirtuin 6 is
associated with release of high mobility group box-1 after cerebral
ischemia. Biochem Biophys Res Commun. 438:388–394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Schwer B, Schumacher B, Lombard DB, Xiao
C, Kurtev MV, Gao J, Schneider JI, Chai H, Bronson RT, Tsai LH, et
al: Neural sirtuin 6 (Sirt6) ablation attenuates somatic growth and
causes obesity. Proc Natl Acad Sci USA. 107:21790–21794. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chen X, Hao B, Liu Y, Dai D, Han G, Li Y,
Wu X, Zhou X, Yue Z, Wang L, et al: The histone deacetylase SIRT6
suppresses the expression of the RNA-binding protein PCBP2 in
glioma. Biochem Biophys Res Commun. 446:364–369. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Santandreu FM, Brell M, Gene AH, Guevara
R, Oliver J, Couce ME and Roca P: Differences in mitochondrial
function and antioxidant systems between regions of human glioma.
Cell Physiol Biochem. 22:757–768. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Van Meter M, Mao Z, Gorbunova V and
Seluanov A: SIRT6 overexpression induces massive apoptosis in
cancer cells but not in normal cells. Cell Cycle. 10:3153–3158.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Trachootham D, Alexandre J and Huang P:
Targeting cancer cells by ROS-mediated mechanisms: A radical
therapeutic approach? Nat Rev Drug Discov. 8:579–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shi J, Sun B, Shi W, Zuo H, Cui D, Ni L
and Chen J: Decreasing GSH and increasing ROS in chemosensitivity
gliomas with IDH1 mutation. Tumour Biol. 36:655–662. 2015.
View Article : Google Scholar
|
|
51
|
Stechishin OD, Luchman HA, Ruan Y, Blough
MD, Nguyen SA, Kelly JJ, Cairncross JG and Weiss S: On-target
JAK2/STAT3 inhibition slows disease progression in orthotopic
xenografts of human glioblastoma brain tumor stem cells. Neuro
Oncol. 15:198–207. 2013. View Article : Google Scholar :
|
|
52
|
Zheng Q, Han L, Dong Y, Tian J, Huang W,
Liu Z, Jia X, Jiang T, Zhang J, Li X, et al: JAK2/STAT3 targeted
therapy suppresses tumor invasion via disruption of the
EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in
EGFRvIII-expressing glioblastoma. Neuro Oncol. 16:1229–1243. 2014.
View Article : Google Scholar : PubMed/NCBI
|
